Stryker's Trevo stroke device hot on Covidien's heels with positive pivotal data
This article was originally published in Clinica
A pivotal trial of Stryker's Trevo, a device for removing clots in the blood vessels of ischaemic stroke patients, has met its primary endpoint, paving the way for US approval. Stryker plans to use the data from the study, TREVO 2, in a 510(k) application with the FDA; the firm previously told Clinica that it anticipates clearance in late 2012 or early 2013 (www.clinica.co.uk, 1 December 2011).
You may also be interested in...
The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.